EUCTR2021-002535-39-BE进行中（未招募）1 期
Phase 2a, single center, randomized, double-blind, controlled study to evaluate the immunogenicity and the safety of one single administration of OVX836 influenza vaccine at two dose levels (300µg and 480µg) given intramuscularly (IM), in comparison to OVX836 influenza vaccine at 180µg and placebo given IM in healthy subjects aged 18-55 years and in healthy subjects aged 65 years and older. - OVX836-003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Osivax
- 入组人数
- 238
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent.
- •2.Healthy male or female subjects, as determined by medical history and medical examination.
- •3.Between the ages of 18 and 55 years, inclusive, in the pilot phase and the first, younger age cohort; aged 65 years and older in the second, older age cohort.
- •4.Subject who has fully been vaccinated with licensed SARS-CoV-2 (COVID-19) vaccine(s) according to national recommendations for the corresponding population group.
- •5.Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures.
- •6.Ability and technical possibility for completing an e-diary and e-PRO in the pilot phase and the first, younger age cohort; ability for completing a paper diary in the second, older age cohort.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 138
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Subjects with a body mass index (BMI) =19 kg/m² or =35 kg/m² on the day of vaccination
- •2.In the pilot phase and the first younger age cohort only: Previous influenza vaccination within 6 months before the day of vaccination or planned to receive during the study duration.
- •3.Any known or suspected immunodeficient conditions.
- •4.Past or current history of significant autoimmune diseases, as judged by the Investigator.
- •5.Current history of uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases.
- •6.Known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
- •7.Female subjects: pregnant, breast-feeding or of childbearing potential without appropriate contraceptive methods in place for 2 months before enrolment, or with positive pregnancy test on the day of vaccination. Appropriate contraceptive methods are to be maintained until the end of the trial.
- •8.Having received another vaccination within 3 months prior to the day of study vaccination for live attenuated vaccines, or within 1 month prior to the day of study vaccination for inactivated vaccines, except COVID-19 vaccine.
- •9.Planning to receive other vaccines during the first 28 days following the study vaccine administration, except COVID-19 vaccine.
- •10.Administration of any investigational or non-registered drug or vaccine within 3 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period.
- •11.History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period.
- •12.Presence of an acute febrile illness on the day of vaccination (oral temperature >38.0°C, temporary exclusion criterion).
- •13.Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
- •14.Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
- •15.Past (stopped less than 6 months before enrolment) or current history of alcohol or drug abuse, or current smoking habit above 10 cigarettes per day, or current vaping.
- •16.Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800µg/day beclomethasone or equivalent; occasional inhaled corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 30 days before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator.
- •17.History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin.
- •18.Any contraindication to IM administration, as judged by the Investigator.
- •19.Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- •20.Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted, including children of newly composed families.
研究者
相似试验
进行中（未招募）
不适用
Phase II, single centre, randomised, double-blind, placebo-controlled study to determine the efficacy, safety and tolerability of PSD502 in the management of pain in subjects undergoing treatment for acute minor burnsAcute minor burnsEUCTR2005-004653-96-GBPlethora Solutions Limited50
进行中（未招募）
不适用
Phase IIa, single-center, randomized, double-blind, vehicle-controlled study to determine the efficacy and safety/tolerability of a topical riluzole formulation in patients with atopic eczema - Atopic eczemaEUCTR2006-006653-27-DEBiofrontera Bioscience GmbH
进行中（未招募）
不适用
Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Tarenflurbil Spray or PlaceboEUCTR2011-002571-42-DEGALENpharma GmbH
进行中（未招募）
不适用
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.EUCTR2004-004022-27-ESF.Hoffmann - La Roche Ltd160
进行中（未招募）
不适用
A Phase 2, Multicenter, Randomized, Double?blind, Placebo?controlled, Parallel?group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma - NAEUCTR2004-000046-21-SECentocor BV300